A Study to Determine the Bioequivalence of Two Doses of Tafamidis
Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
Study to characterize the bioequivalence of a 12.2 mg free acid tablets compared to
commercial supply (tafamidis meglumine soft gelatin 20 mg capsule) in healthy participants
under fasted conditions.